737 results on '"Pott, Christiane"'
Search Results
2. The gray area of RQ-PCR-based measurable residual disease: subdividing the “positive, below quantitative range” category
3. Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines
4. The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network
5. Limiting environmental reporting flexibility: investor judgment based on the EU taxonomy
6. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
7. Minimale Resterkrankung bei indolenten Lymphomen
8. COVID-19 pandemic and capital markets: the role of government responses
9. Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial
10. EuroClonality-NGS recommendations for evaluation of B cell clonality analysis by next-generation sequencing – a structured approach with the DEPART algorithm
11. Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study
12. Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials
13. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
14. Marker für minimale Resterkrankung: Minimal Residual Disease
15. The Risk of Silence—How the Capital Market Penalizes Social Media Passivity
16. Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study
17. Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders
18. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
19. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL
20. Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions
21. Maligne Lymphome – Quo vadis?: Welche Entwicklungen erwarten uns in der Diagnostik und Therapie?
22. The impact of changes to auditors' reporting and audit committee strength on bank directors' perceptions and decisions: An experimental investigation.
23. Genetic drivers in the natural history of chronic lymphocytic leukemia development as early as 16 years before diagnosis
24. MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial
25. Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.
26. P601: GENETIC DRIVERS IN THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA DEVELOPMENT AS EARLY AS 16 YEARS BEFORE DIAGNOSIS
27. The Impact of Corporate Social Responsibility Disclosure on Corporate Reputation: A Non-professional Stakeholder Perspective
28. ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma
29. Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS
30. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS
31. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study
32. Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry)
33. Favorable radiation field decrease in gastric marginal zone lymphoma: Experience of the German Study Group on Gastrointestinal Lymphoma (DSGL)
34. LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting
35. Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
36. Governance Kodizes in NPOs
37. Long‐term outcome in patients with mantle cell lymphoma following high‐dose therapy and autologous stem cell transplantation
38. Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance
39. DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy
40. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR
41. Table S3 from MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma
42. Supplementary Tables from Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1)
43. Figure S2B from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
44. Supplementary Figures from Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1)
45. Table S1 from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
46. Table S2, Table S4, Table S6, Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Supplementary Methods from MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma
47. Steuerung und Kontrolle von öffentlichen Unternehmen
48. Data from Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1)
49. Supplementary Methods from Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1)
50. Data from MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.